

Patient Name: DOE, JANE			Specimen Number: C24-000533					
Patient Rec. #:			A	Alliance ID:				
Date of Birth:	05/19/1958	Age: 66	Orde	ering Client:	THE BEST PHYSIC	IAN		
Sex:	Female		Ordering	Physician:	THE BEST PHYSIC	IAN		
Date Collected:	05/23/24	nt Address:	ss: 7200 W Camino Real					
Date Received:	05/23/24	BOCA RATON, FL 33433						
Date Reported:	05/29/24			Telephone:	(561) 453-1234	Fax:(56	1) 453-1238	В
			CC	Physician:				
			<b>CYTOLOGY REPOR</b>	Т				
DOE, JANE		INTERPRE	ΓΑΤΙΟΝ		100	1.6		
Specimen #: C24-	men #: C24-000533 POSITIVE FOR MALIGNANT CELLS		5	4 -		5		

PAPILLARY THYROID CARCINOMA (Bethesda category VI) Date: 05/23/24 **MICROSCOPIC DESCRIPTION** The specimen demonstrates a cellular sample composed of neoplastic cells with nuclear pleomorphism including irregular nuclear membranes, fine and powdery chromatin with nuclear grooves and intranulear cytoplasm invaginations (INCI). Colloid is virtually absent. SOURCE OF SPECIMEN Thyroid, left nodule, fine needle aspiration SPECIMEN ADEQUACY Satisfactory for evaluation **GROSS DESCRIPTION** FNA, 8 ml of pale pinkish clear fluid is received in CytoLyt fixative with the patient second identifiers. 2 CellSolutions F50 slides prepared. Residual cell pellet is prepared for cell block. (CellSolutions F50: PAPx1 & H&Ex1 ; Cell block: 2levels, H&Ex2) **CLINICAL HISTORY** Thyroid, left nodule, 3 cm **CELL BLOCK** The cell block sections exhibit papillary patterns consistent with papillary thyroid carcinoma NOTES Category Risk of malignancy Usual management \_\_\_\_\_ 5-10% I. Non-DX Repeat FNA with ultrasound guidance II. Benign 0-3% Clinical and sonographic follow-up III.AUS/FLUS ~10-30% Repeat FNA, molecular testing, or lobectomy IV. FN/SFN Molecular testing, lobectomy 25-40% V. Suspicious 50-75% Near-total thyroidectomy or lobectomy VI. Malignant 97-99% Near-total thyroidectomy or lobectomy \_\_\_\_\_ Woosung J Park, CT(ASCP) SCREENED BY: **REVIEWED BY:** Electronically REVIEWED BY: Ali Tamsen, M.D. Board Certified in Anatomic Pathology Date: 05/29/2024 Time: 12:06:04 **CPT CODES** 88173 END OF REPORT

The tests utilizing analyte-specific reagents (ASR) were developed and their performance characteristics determined by Alliance Laboratories as required by CLIA '88 regulations. They have not been cleared or approved for specific uses by the USE food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. These tests are used for clinical purposes. Alliance Laboratories 7200 W Camino Real Suite 330, Boca Raton, FL 33433 Phone Number: (561) 453-1234 Fax Number: (561) 453-1238

C24-000533